ArticleAnnals of the rheumatic diseases2016
Monocyte type I interferon signature in antiphospholipid syndrome is related to proinflammatory monocyte subsets, hydroxychloroquine and statin use.
Article in Annals of the rheumatic diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Pooled it
- Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sjögren's syndrome in the JOQUER randomized trial.Rheumatology (Oxford, England) · 2020Trial
- Type I Interferon Signature in Primary Antiphospholipid Syndrome: Clinical and Laboratory Associations.Frontiers in immunology · 2019Trial
- Immunohistochemical analysis reveals higher Myxovirus resistance protein 1 expression and increased macrophage count in placentas from patients with systemic rheumatic diseases.Rheumatology international · 2025Article
- Review
- Association of autoantibodies with the IFN signature and NETosis in patients with systemic lupus erythematosus.Journal of translational autoimmunity · 2024Article
- Kidney whole-transcriptome profiling in primary antiphospholipid syndrome reveals complement, interferons and NETs-related gene expression.Rheumatology (Oxford, England) · 2024Article
- Antiphospholipid Antibodies as Key Players in Systemic Lupus Erythematosus: The Relationship with Cytokines and Immune Dysregulation.International journal of molecular sciences · 2024Review
- Clinical Management of Thrombotic Antiphospholipid Syndrome.Journal of clinical medicine · 2022Review
- An Update on Antiphospholipid Syndrome.Current rheumatology reports · 2022Review
- Dendritic Cells and Antiphospholipid Syndrome: An Updated Systematic Review.Life (Basel, Switzerland) · 2021Review
- A new molecular classification to drive precision treatment strategies in primary Sjögren's syndrome.Nature communications · 2021Article
- Utilizing type I interferon expression in the identification of antiphospholipid syndrome subsets.Expert review of clinical immunology · 2021Review
- NETs in APS: Current Knowledge and Future Perspectives.Current rheumatology reports · 2020Review
- Immune Modulation as a Therapeutic Option During the SARS-CoV-2 Outbreak: The Case for Antimalarial Aminoquinolines.Frontiers in immunology · 2020Review
- An Easy and Reliable Strategy for Making Type I Interferon Signature Analysis Comparable among Research Centers.Diagnostics (Basel, Switzerland) · 2019Article
- Alarmin HMGB1 and Soluble RAGE as New Tools to Evaluate the Risk Stratification in Patients With the Antiphospholipid Syndrome.Frontiers in immunology · 2019Article
- Update on Antiphospholipid Syndrome: Ten Topics in 2017.Current rheumatology reports · 2018Review
- Antiphospholipid Syndrome Nephropathy: From Pathogenesis to Treatment.Frontiers in immunology · 2018Review
Corrections and comments
- Commented on by
- Comment on
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
27689737What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.